keyboard_arrow_up

Botswana Pharmaceutical Industry Research Report

Most up-to-date research on "The Pharmaceutical Market: Botswana" to its huge collection of research reports.

OVERVIEW OF THE PHARMACEUTICAL MARKET IN BOTSWANA

Growing appreciation of the value of a healthy population, combined with improvements in its economy, will boost investments in medical services. The healthcare system is largely government-funded, and therefore people on low incomes are able to seek medical treatment. However, communication and transport hindrances as well as poor utilisation of existing healthcare services in rural areas means uptake is low. Consequently, it is unlikely Botswana will be of major significance to pharmaceutical and healthcare firms in the short or medium term.


Headline Expenditure Projections:

  • Pharmaceuticals: BWP1.50bn (US$200mn) in 2012 to BWP1.65bn (US$200mn) in 2013; +10.0% in local currency terms and +0.4% in US dollar terms.
  • Healthcare: BWP11.56bn (US$1.52bn) in 2012 to BWP12.48bn (US$1.49bn) in 2013; +8.0% in local currency terms and -1.4% in US dollar terms.

Risk/Reward Rating:

Botswana's Pharmaceutical Risk/Reward Rating (RRR) score for Q1 13 is unchanged from the previous quarter. This is also the case for all other countries in BMI's proprietary system that ranks pharmaceutical markets according to attractiveness to multinational drugmakers. A minor re-weighting of one of the RRR components is being implemented to improve the tool, and the adjusted scores for all markets will be published in the Q3 13 updates of the Pharmaceuticals & Healthcare reports. Botswana has a RRR score of 45.2 out of 100, making it the 16th most attractive pharmaceutical market in Middle East and Africa.


Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Related Reports
Uzbekistan Pharmaceuticals & Healthcare Report We maintain the view that risk-averse pharmaceutical, healthcare and medical device companies should avoid Uzbekistan . While the country has a definite need for pharmaceuticals and medical devices, the regulatory environment remains opaque and state-dominated. Moreover, the government is committed to boosting Uzbekistan's...

OVERVIEW OF THE PHARMACEUTICAL MARKET IN CHINA We remain bullish on China's pharmaceutical sector despite the slowdown in the economy and political reshuffle. We do not think the reshuffle will have any adverse changes or cause any reversals to healthcare reform given that the country has been rolling out various healthcare schemes in 2012 and that a key person overseeing...

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact: